Imagine a heart pump that doesn't actually touch the blood, acting more like a supportive sleeve around the heart. This removes the need for risky blood-thinning drugs that often cause strokes or bleeding. It's a simpler, safer way to help both sides of a failing heart pump blood to the body.
Current heart failure treatments are limited by a shortage of donor organs and the high risk of strokes and bleeding caused by blood-contacting pumps.
A biventricular support system consisting of a minimally invasive implant and an electro-pneumatic drive unit that supports the heart without contacting blood.
If you are a manufacturer dealing with the high complication rates of blood-contacting pumps — this project developed reBEAT, a device that avoids blood contact entirely. This reduces the risk of stroke and ischemia for the 800,000 patients suffering from advanced heart failure.
If you are a clinic dealing with long transplant waitlists and restrictive VAD usage — this project developed a system that can be implanted in about 40 minutes. It provides a viable alternative for the <3% of patients currently receiving treatment.
If you are an insurer dealing with the extreme costs of heart transplants — this project developed a technology that offers high cost effectiveness at <50% of the cost of transplants and VADs.
The reBEAT system offers high cost effectiveness, costing <50% of what heart transplantations and traditional VADs cost.
Yes, there is a massive addressable market with over 800,000 patients worldwide suffering from advanced heart failure.
Based on available project data, the technology is developed and manufactured by AdjuCor GMBH, though specific licensing terms are not listed.
The project focused on reaching the final pre-market clinical study and executing the world's first-in-human study for this type of device.
AdjuCor expects to reach revenues of 69M€ by 2027.
The project is led by a single SME, AdjuCor GMBH, based in Germany. With a 100% industry ratio and no university or research partners, the project is purely commercially driven, focusing on manufacturing optimization and clinical market entry rather than basic research.
Contact AdjuCor GMBH in Munich, Germany
Contact us to explore licensing or partnership opportunities with AdjuCor.
